FINAL/APPROVED

VIRGINIA BOARD OF PHARMACY
MINUTES OF FULL BOARD MEETING

Tuesday, September 30, 2025

Department of Health Professions
Perimeter Center
9960 Mayland Drive
2nd Floor Conference Center, Board Room 2
Henrico, Virginia 23233

CALL TO ORDER:	A full board meeting was called to order at 9:05 AM.
PRESIDING:	**Larry Kocot,** JD, Chairman
MEMBERS PRESENT:	**Shannon Dowdy,** PharmD, Vice Chair **Michelle Hoffer,** JD **Kelly Hasty Kale,** RPh **Wendy Nash,** PharmD **Kristopher Ratliff,** DPh **Patricia Richards-Spruill,** RPh **Tim Robertson,** RPh **Derek Webb,** PharmD **Ling Yuan,** PharmD
STAFF PRESENT:	**Erin Barrett**, JD, DHP Director of Legislative and Regulatory Affairs **Sorayah Haden**, Executive Assistant **Caroline Juran**, RPh, Executive Director **Ryan Logan**, RPh, Deputy Executive Director **Beth O'Halloran**, RPh, Deputy Executive Director **Arne Owens**, DHP Agency Director **Jim Rutkowski,** JD, Senior Assistant Attorney General **Ellen Shinaberry**, PharmD, Deputy Executive Director
PHARMACISTS AWARDED 1-HOUR OF LIVE OR REAL-TIME INTERACTIVE CONTINUING EDUCATION FOR ATTENDING MEETING:	Kelly Hasty Kale, RPh
QUORUM:	With 10 members present, a quorum was established.
APPROVAL OF AGENDA:	An amended agenda was provided that included a new agenda item under the New Business section entitled "Excerpt of 2024 Pharmacist Workforce Report

regarding immunizations". Four handouts were also provided: information regarding the proposed regulations on Crisis Stabilization Services and Use of Automated Drug Dispensing Systems and Remote Dispensing Systems, an Excerpt of the 2024 Pharmacist Workforce Report regarding Immunizations, an excerpt of the 2025 NABP Survey of Pharmacy Law regarding Remote Pharmacy Practice, and information regarding the Pharmacist Vaccine Statewide Protocol for Persons Eighteen Years of Age and Older. Hearing no comment, the amended agenda was approved as presented.

APPROVAL OF PREVIOUS BOARD MEETING MINUTES

Amendments were offered to the draft minutes included in the agenda packet. There was a brief discussion regarding the approval of minutes for meetings that certain members did not participate in. Ms. Barrett stated that the purpose of the board's approval was for staff to post the final minutes and that the approval was not necessarily to affirm the accuracy of the minutes.

MOTION:

The Board voted unanimously to amend the draft minutes on page 23 of the agenda packet to read "and", instead of "as" following "reinstate the pharmacist license of Edgar Gonzalez", to correct the spelling of Dr. Ratliff's name on page 25 of the agenda packet, and to approve the minutes from May 7, 2025 to September 9, 2025 to be posted. (motion by Kale, seconded by Webb)

PUBLIC COMMENT:

Dr. Natalie Nguyen, on behalf of the Virginia Society of Health-System Pharmacists (VSHP), thanked the board for its engagement and continued collaboration with pharmacy professional groups on ensuring access to pharmacy services in the Commonwealth. Regarding draft amendments to guidance document 110-39, she recommended the revision on clarifying when a CSR is to be considered with the proposed language:
"Sites that are not covered by a hospital pharmacy license such as off-site ambulatory care clinics and free-standing emergency departments that are under the control of a health-system may require a controlled substances registration. This includes offsite locations using automated drug dispensing devices to store non-patient specific compounded drug products that are under the control of the health-system. Refer to Guidance Document 110-19." Additionally, VSHP requests a timely notification regarding the statewide protocol implementation to ensure access to care. Her comments were provided in writing to Ms. Juran via email during the meeting.

Jamie Fisher, Executive Director of the Virginia Pharmacy Association (VPhA), expressed appreciation for the board's continued work within the pharmacy industry. VPhA was pleased with the recently held Therapeutic Interchange Workgroup meeting and offers support. VPhA requests that the vaccine statewide protocol for adults be amended to allow pharmacy technicians to administer vaccines. VPhA continues to monitor pharmacy working conditions and welcomes collaboration with the board.

DHP DIRECTOR'S REPORT:

Arne Owens provided the DHP Director's Report consisting of the following updates:

- The pending federal government shutdown will not affect the Virginia Department of Health Professions (DHP) excluding the financial grant awarded to the Prescription Monitoring Program.
- The agency is focused on monitoring and managing its finances appropriately and cutting expenses where it can.
- DHP has submitted legislative proposals for consideration for the upcoming General Assembly session, but no approval yet.
- In response to a specific question of a board member, he stated that the rural health funding could possibly assist with addressing the concerns of pharmacy closures in rural areas.

LEGISLATIVE/ REGULATORY/GUIDANCE

CHART OF REGULATORY ACTIONS

Ms. Barrett reviewed the Regulatory Chart included in the agenda packet and provided the following report as of September 17, 2025:

- There are two bills under review in the Governor's Office:
  - 18VAC110-20 – Prohibition Against Incentives to Transfer Prescriptions (Final)
  - 18VAC110-20 – Implementation of 2021 Periodic Review (NOIRA)
- There are seven bills under review in the Secretary's Office:
  - 18VAC110-21 Implementation of 2021 Periodic Review (NOIRA)
  - 18VAC110-30 – Implementation of 2021 Periodic Review (Proposed)
  - 18VAC110-20, 18VAC110-21, 18VAC110-30, and 18VAC110-50 – Increase in Fees (Final)
  - 18VAC110-20 – Replacement of Analytic Lab Regulation for Pharmaceutical Processors (Fast-Track)
- There is one bill under review at the Office of Attorney General:
  - 18VAC110-20 – Inclusion of Opioid Antagonists in Regulations Referring to Naloxone (Fast-Track)
- There are 14 bills that have recently become effective or awaiting publication.

ADOPT EXEMPT REGULATORY ACTION – ADDITION OF CHEMICALS TO SCHEDULE I

The Board reviewed the recommendation of the Department of Forensic Science and draft amendments of 18VAC110-20-322.

MOTION

The Board voted unanimously to adopt the exempt changes to 18VAC110-20-322 to add the following chemicals to Schedule I:
1. The following compound classified as a synthetic opioid: N-(2-

methylphenyl)-1-(2-phenylethyl)piperidin-4-amine (other name: Despropionyl o-methylfentanyl), its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.

2. The following compounds expected to have hallucinogenic properties:

a. [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] propanoate (other names: 4-propionoyloxy-N,N-dimethyltryptamine, 4-propanoyloxy DMT, 4-ProO DMT), its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

b. 1-(1,3-benzodioxol-5-yl)-2-(2-methylpropylamino)propan-1-one (other names: 3,4-methylenedioxy-N-isobutylcathinone; N-isobutyl methylone; 3,4-methylenedioxy-α-isobutylaminopropiophenone), its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

c. 2-bromo-Deschloroketamine (other name: 2-(2-bromophenyl)-2-(methylamino)-cyclohexanone), its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

3. The following compound expected to have depressant properties: 1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine (other name: Nitrazolam), its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

4. The following compounds classified as cannabimimetic agents:

a. Naphthalen-1-yl 3-(dimethylsulfamoyl)-4-methylbenzoate (other names: NMDMSB; 1-naphthyl 3-(dimethylsulfamoyl)-4-methylbenzoate), its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

b. N-[1-(5-fluoropentyl)-2-hydroxyindol-3-yl]iminobenzamide (other names: 5-fluoro BZO-POXIZID, 5-fluoropentyl MDA 19), its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation. (motion by Webb, seconded by Yuan)

ADOPT EXEMPT REGULATORY ACTION TO CONFORM TO RECENT FEDERAL SCHEDULING ACTION OF FENTANYL CLASSIFICATION

The Board reviewed the draft changes to 18VAC110-20-323 and an excerpt of HR27 showing federal changes to Schedule I to include fentanyl-related substances.

MOTION:

The Board voted unanimously to amend 18VAC10-20-323 by exempt action as presented. (motion by Dowdy, seconded by Hoffer)

ADOPT FINAL REGULATIONS FOR ALLOWANCES FOR EMERGENCY DRUGS BY EMS AGENCIES

The Board reviewed and discussed the draft final language regarding allowances for emergency drugs by EMS agencies.

MOTION:

The Board voted unanimously to adopt final regulations as presented and amended by striking "pharmacy's" in 18VAC110-20-505 (B)(2) to read "...verify that all drugs have been accurately tagged prior to storing the drugs in the inventory". (motion by Webb, seconded by Yuan)

ADOPT FAST-TRACK REGULATORY AMENDMENT OF 18VAC110-20-590 REGARDING CORRECTIONAL FACILITIES POSSESSING LONG-ACTING MEDICATIONS

The Board reviewed and discussed SB 1367 passed during the 2025 General Assembly Session and draft amendments to 18VAC110-20-590.

MOTION:

The Board voted unanimously to adopt fast-track regulatory amendments of 18VAC110-20-590 as presented to allow correctional facilities to possess certain long-acting medications in bulk. (motion by Ratliff, seconded by Hoffer)

ADOPT PROPROSED REGULATIONS RELATED TO CENTRAL FILL PHARMACIES

The Board reviewed and discussed the proposed draft language regarding central fill pharmacies, Town Hall Emergency/NOIRA stage summary, two public comments received, and HB 1068 from the 2024 General Assembly Session. There was some discussion regarding the requests for amendment from the public commenters. Dr. Yuan asked if such an amendment would allow remote verification of sterile compounded products. There was a request for more information regarding existing innovative pilots involving Riverside Health System remotely verifying sterile compounds and CVS Air Support.

MOTION:

The Board voted unanimously to defer the discussion and vote to the Regulatory Committee in November. (motion by Webb, seconded by Dowdy)

ADOPT PROPOSED REGULATIONS RELATED TO EXCLUSION OF PRIVATE DWELLINGS FROM CONTROLLED SUBSTANCES

The Board reviewed and discussed the proposed draft language regarding the exclusion of private dwelling and residences from controlled substances

REGISTRATIONS	registration locations and the Town Hall summary.
MOTION:	**The Board voted unanimously to adopt the proposed regulatory amendment of 18VAC110-20-690 as presented to exclude private dwellings from serving as a site for a controlled substances registration. (motion by Hoffer, seconded by Richards-Spruill)**
INITIATE PERIODIC REVIEW OF CHAPTER 15 REGARDING AGENCY SUBORDINATES	The Board reviewed and discussed 18VAC110-15 Regulations Governing Delegation to an Agency Subordinate.
MOTION:	**The Board voted unanimously to initiate a periodic review of 18VAC110-15. (motion by Dowdy, seconded by Hoffer)**
ADOPT EXEMPT REGULATORY AMENDMENTS REGARDING ADVANCED REGISTERED MEDICATION AIDES	The Board reviewed and discussed excerpts of HB2468 and draft amendments of 18VAC110-20-555 and 18VAC110-20-560.
MOTION:	**The Board voted unanimously to adopt exempt regulatory amendments of 18VAC110-20-555 and 18VAC110-20-560 as presented. (motion by Webb, seconded by Dowdy)**
RE-ADOPTION OF GUIDANCE DOCUMENT 110-19, USE OF AUTOMATED DISPENSING DRUG SYSTEMS AND REMOTE DISPENSING SYSTEMS IN CERTAIN FACILITIES	At the request of the Office of Regulatory Management, the Board reviewed and discussed additional amendments to Guidance Document 110-19.
MOTION:	**The Board voted unanimously to re-adopt Guidance Document 110-19 as presented. (motion by Hoffer, seconded by Ratliff)**
ADOPT GUIDANCE DOCUMENT 110-39 REGARDING HOSPITAL CENTRALIZED COMPOUNDING	The Board reviewed and discussed Guidance Document 110-39 based on the public comment received from VSHP.
MOTION:	**The Board voted unanimously to adopt Guidance Document 110-39 as presented and amended by changing the first sentence of the second**

paragraph to read "Facilities within a health system under common ownership with the pharmacy using automated drug dispensing devices..." (motion by Hoffer, seconded by Richards-Spruill)

ADOPT AMENDMENT TO GUIDANCE DOCUMENT 110-8 TO REMOVE REFERENCE TO TPA FORMULARY FOR OPTOMETRISTS DUE TO LEGISLATIVE CHANGE

The Board reviewed and discussed redline proposed changes to Guidance Document 110-8, the pending exempt regulatory changes made by the Board of Optometry to implement HB1898 and SB1081, and HB1898.

MOTION:

The Board voted unanimously to amend Guidance Document 110-8 as presented. (motion by Dowdy, seconded by Webb)

AMEND GUIDANCE DOCUMENT 110-17 REGARDING TOEFL SCORES

The Board reviewed and discussed excerpts from the FPGEC 2025 candidate application bulletin and draft amendments of Guidance Document 110-17.

MOTION:

The Board voted unanimously to amend Guidance Document 110-17 as presented and amended by inserting the date range of "March 1, 2024 through October 24, 2025" within the instructions for graduates of foreign schools of pharmacy. (motion by Ratliff, seconded by Webb)

<u>OLD BUSINESS</u>

REVIEW ACTION ITEMS FROM PREVIOUS MEETINGS

The Chairman reviewed the Action Items list from previous meetings that was included in the agenda packet.

ACTION ITEM:

Regarding action item #1, "The board will discuss at a future meeting how it wants to be informed of working condition cases that indicate a violation of 18VAC110-20-113.", the members requested staff to provide a quarterly report of cases involving working condition regulation 18VAC110-20-113, along with sanctions, and context of the cases.

ACTION ITEM:

Regarding action item #2, the Board will discuss the possibility of convening an ad hoc inspection committee meeting to discuss inspection reports at the December Full Board Meeting.

ACTION ITEM:

He stated that action items 3, 4, and 5 may be best addressed by ad hoc committees. Regarding action item #3, "The board will discuss at a future meeting if the bylaws should be amended to have more than two members appointed to the innovative pilot committee. Board members will provide staff with potentially other subjects in the bylaws that it may

consider amending in advance of such meeting for research purposes.", the Chairman announced that he intends to appoint an ad hoc committee to review the Bylaws. The committee can also review action item #4 regarding its current process for accepting a license for surrender to ensure it is captured appropriately in the bylaws. He stated that he will provide more information soon.

ACTION ITEM:

Regarding action item #6, "Actions in Virginia that resulted from the 2013 NABP Report of the Task Force on the Regulation of Pharmacy Benefit Managers", the Chairman briefly reviewed information in the agenda packet regarding a PBM Task Force convened by DHP in 2016. **The members requested staff to research which state boards of pharmacy are currently regulating PBMs, how effective Mississippi is in regulating them, and to research with counsel if the board could define the term "specialty drug" and require third-party insurances to adhere to the definition.**

ACTION ITEM:

Regarding action item #7, "Staff will ask the agency's Finance Department if they actively negotiate credit card fees", Ms. Juran informed the Board that credit card fees are handled through a statewide contract managed by the Department of Treasury, that agency representatives have begun talks with Treasure representatives to discuss options for managing credit card fees, and that more information will be provided when available.

ACTION ITEM:

Regarding action item #8, Ms. Juran stated that staff will include a link to the staffing requests or concerns form related to pharmacy working conditions to licensees in an upcoming blast email communication.

ACTION ITEM:

Regarding action item #9, "Staff will ask the deans of the four schools of pharmacy in Virginia if information regarding the working condition regulations is being taught in schools. Staff will also offer to provide a presentation to the students to educate students to this topic.", Ms. Juran reported the following: VCU includes the working condition regulation in its law teachings; it does not appear to be currently included in the other schools' law teachings but that the deans will pass along the information to the law class professors. Ms. Juran also stated that she recently provided a law update presentation, including the working condition regulation, to Appalachia College of Pharmacy students and VCU School of Pharmacy students. Dr. Webb and Dr. Ratliff offered remarks during the Appalachia presentation and Dr. Dowdy offered remarks during the VCU presentation. **Ms. Juran will present to Shenandoah in the spring and the date for Hampton is not yet final. Deans Mayhew, Kidd, and Iyer will provide an update to the board regarding school activities at the December full board meeting.**

Ms. Juran stated that action item #10, "Ms. Juran will email VPhA and VSHP to encourage them to educate members on suicide awareness." has been completed.

NEW BUSINESS

AMEND STATEWIDE PROTOCOLS

To ensure the statewide protocols remain consistent with standard of care, representatives from the Board of Medicine, Board of Pharmacy, and Virginia Department of Health individually reviewed all statewide protocols in August and offered suggested edits to Ms. Juran to present to the full board for its consideration.

VACCINE STATEWIDE PROTOCOL FOR PERSONS EIGHTEEN YEARS OF AGE OR OLDER

The Board reviewed a handout of draft amendments to the adult vaccine protocol which authorized administration consistent with the CDC Immunization Schedules. The Advisory Committee on Immunization Practices had recently offered recommendations but the CDC Director had not yet approved the recommendations for amending the Immunization Schedules. Mr. Robertson highlighted the need for pharmacy technicians to administer the COVID-19 vaccine. The law under which the Health Commissioner recently issued a standing order for pharmacists to administer COVID-19 vaccines, Va. Code 54.1-3408(I) does not include an allowance for pharmacy technicians to administer. The Board recommended additional edits to the draft handout to authorize pharmacists to administer the COVID-19 vaccine or direct pharmacy interns or pharmacy technicians to administer the COVID-19 vaccine under pharmacist supervision, consistent with the manufacturer's directions or the CDC Immunization Schedules. All other adult vaccines are to be administered pursuant to the CDC Immunization Schedules.

MOTION:

The Board voted unanimously to amend the vaccine statewide protocol for persons eighteen years of age or older as presented in the handout and to direct staff to further amend the handout by inserting an allowance to authorize pharmacists to administer the COVID-19 vaccine or direct pharmacy interns or pharmacy technicians to administer the COVID-19 vaccine under pharmacist supervision, consistent with the manufacturer's directions or the CDC Immunization Schedules, and to delegate the review of the final document prior to posting to the Chairman. (motion by Webb, seconded by Yuan)

The Board reviewed the draft amendments to the other statewide protocols as included in the agenda packet.

MOTION:

The Board voted unanimously to amend the following statewide protocols as presented and amended as indicated below:

- **Vaccine Statewide Protocol for Persons Ages Three through Seventeen (as presented);**

- **Pharmacist Hormonal Contraceptive Statewide Protocol (as presented);**
- **Pharmacist Naloxone or Other Opioid Antagonist Statewide Protocol (as presented);**
- **Pharmacist Protocol for Testing and Initiating Treatment for Influenza (as presented);**
- **Tuberculin Skin Testing One-Step Protocol (as presented);**
- **Tuberculin Skin Testing Two-Step Protocol (as presented);**
- **Pharmacist Epinephrine Statewide Protocol (as presented);**
- **Pharmacist Protocol for Testing and Initiating Treatment for Acute Group A Streptococcus Bacteria Infection (as presented and amended by inserting "or ASHP Drug Shortages List" on page 292 of the agenda packet under *Drug Inclusion Criteria* after "FDA Drug Shortages List" and change "OTC" to "over-the-counter" on page 293 and anywhere else in the document. (motion by Yuan, seconded by Dowdy).**

AD HOC COMMITTEES

The Chairman provided the following information regarding his announcement of ad hoc committees. He is currently drafting committee charges. Recommendations will be referred to the full board.

Bylaws Committee will be chaired by Dr. Webb. It will have no more than 4 members.
Health Data Committee will be chaired by Dr. Nash.
Communications and Outreach will be chaired by Ms. Richards-Spruill.

EXCERPT OF 2024 PHARMACIST WORKFORCE REPORT REGARDING IMMUNIZATIONS

Dr. Nash referred to the excerpt that was provided as a handout to emphasize the number of pharmacists who indicated that they administer vaccines and participate in statewide protocols and collaborative practice agreements.

REPORTS:

CHAIRMAN'S REPORT

The Chairman provided a report consisting of the following updates:

- He will work with board staff to provide more detail to the board regarding waiver requests and approvals that the full board may not be aware of.
- He expressed his pleasure in working more in-depth with board staff.
- He would like an increase in communication with the workforce to ensure they are more aware of the board's effort.
- He questioned if enough has been done to address pharmacy technician education and workforce shortages. Dr. Ratliff proposed the board investigate alternatives, in lieu of national certification for pharmacy technicians. Additionally, he would like for the board to

research a tiered licensing system as a possible endeavor to assist with pharmacy workforce retention and address challenges to accelerate hiring in small environments, e.g., Level I tech would be responsible for accurately counting and assembling medication; Level II could be nationally certified with greater responsibilities; and Level III techs. Dr. Nash, Dr. Ratliff, and Dr. Dowdy support researching pharmacy technician issue.

ACTION ITEM:

Staff will research if other states allow a tiered licensing approach for pharmacy technicians.

- Board members shared their thoughts and appreciation of the collaborative discussion at the Therapeutic Interchange Workgroup meeting.
- Board will continue to monitor 7-OH, derivative of kratom.
- He will continue to research the policy for board members to appropriately participate virtually in board meetings. There are staffing and resource issues.

LICENSURE PROGRAM

Mr. Logan provided an overview of the Licensure Program consisting of licensing data of Individuals and Facility licensees from Q3 of 2022 through Q4 of 2025. The overview included the following current license count:

- Pharmacist – 16,686
- Pharmacy Technician – 13,520
- Pharmacy Technician Trainee – 7,864
- Pharmacy Intern – 1,041
- Resident Pharmacies – 1,698
- Non-Resident Pharmacies – 997

He reviewed the new pharmacy permit to pharmacy permit closure ratios. As of Q4, the Board has a record of 7 pharmacy permits issued and 33 pharmacy permits closed.

INSPECTION PROGRAM

Ms. O'Halloran provided an overview of the Inspection Program. The overview consisted of all inspections conducted during the period of April 1, 2025 through June 30, 2025. As of June 30, 2025, the Inspections Program conducted a total of 504 inspections consisting of 471 in person inspections and 33 virtual inspections. The top 5 cited deficiencies reported are as follows:

- Compounding facilities and equipment used in performing non-sterile compounds not in compliance with 54.1-3410.2 (cited 23 times)
- Compounded products not properly labeled. (cited 20 times)
- Labels do not include all required information. (cited 17 times)
- Required compounding/dispensing/distribution records not complete and properly maintained. (cited 17 times)
- Repackaging records and labeling are not kept as required or in

compliance. (cited 16 times)

DISCIPLINARY PROGRAM

Dr. Shinaberry provided an overview of the Disciplinary Program. The overview consisted of cases received, opened, and closed from Q4 of 2022 through Q4 2025. As of Q4 of 2025, ending June 30, 2025, the board received 2,244 cases, opened 5,568 cases, and closed 1,878 cases. As of August 27, 2025, the board currently has 349 open cases consisting of 181 patient care related cases and 168 non-patient care related cases.

EXECUTIVE DIRECTOR'S REPORT

Ms. Juran provided an Executive Director's report with the following updates:

- Board staff will resume recruitment for the vacant disciplinary administrative assistant position in January 2026.
- Meetings attended since the May board meeting
- Upcoming meetings
- Presentations given by the board since the May full board meeting.
- Upcoming presentations

CONSIDERATION OF CONSENT ORDERS, SUMMARY SUSPENSIONS, OR SUMMARY RESTRICTIONS

CASE #241716: RACHEL RENEE DRINKARD (PHARMACY TECHNICIAN REGISTRATION #0230-014991)

Jess Webber, DHP Adjudication Specialist presented a consent order for consideration of a possible ratification regarding Rachel Renee Drinkard (Pharmacy Technician Registration #0230-014991).

DECISION:

Upon a motion by Ms. Kale, and duly seconded by Dr. Dowdy, the Board voted unanimously to accept the consent order for ratification of the Pharmacy Technician registration of Rachel Renee Drinkard.

MEETING ADJOURNED: 2:24 PM

Caroline Juran
Caroline Juran, RPh
Executive Director

12/10/2025
DATE: